Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371723 | 1.00 | LMNA (0.33) | LMNAMAPTHTT | |
| SCHEMBL13698408 | 1.00 | LMNA (0.33) | LMNAMAPTHTT | |
| SCHEMBL21340399 | 1.00 | LMNA (0.33) | LMNAMAPTHTT | |
| SCHEMBL12193879 | 0.97 | — | — | |
| SCHEMBL23114323 | 0.87 | — | — | |
| SCHEMBL21673740 | 0.87 | — | — | |
| SCHEMBL20289003 | 0.87 | — | — | |
| SCHEMBL22062986 | 0.84 | HTT (0.31) | HTT | |
| SCHEMBL21340210 | 0.81 | — | — | |
| SCHEMBL24854975 | 0.81 | HTT (0.33) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-02-16 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | Hepagene Therapeutics (HK) Limited (HK) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | NR1H4, FXR1, FXR2 | LMNA 3466/4885MAPT 3342/4885HTT 644/4885 |
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3949/4885MAPT 3355/4885HTT 3486/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | LMNA 3608/4885MAPT 3269/4885HTT 3961/4885 |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | NR1H4, FXR1, FXR2 | LMNA 3466/4885MAPT 3342/4885HTT 644/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3608/4885MAPT 3269/4885HTT 3961/4885 |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 3151/4885MAPT 3275/4885HTT 1576/4885 |
| US-20240067662-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 3908/4885MAPT 3872/4885HTT 2804/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3949/4885MAPT 3355/4885HTT 3486/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | LMNA 3949/4885MAPT 3355/4885HTT 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.